HLB Life Science Co., Ltd. (KOSDAQ:067630)

South Korea flag South Korea · Delayed Price · Currency is KRW
6,440.00
+40.00 (0.63%)
May 13, 2025, 3:30 PM KST
-57.44%
Market Cap 784.56B
Revenue (ttm) 102.24B
Net Income (ttm) 6.14B
Shares Out 121.83M
EPS (ttm) 54.00
PE Ratio 119.26
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 208,455
Average Volume 352,368
Open 6,400.00
Previous Close 6,400.00
Day's Range 6,390.00 - 6,560.00
52-Week Range 5,860.00 - 16,380.00
Beta -0.26
RSI 44.76
Earnings Date May 14, 2025

About HLB Life Science

HLB Life Science Co., Ltd. develops and manufactures in vitro diagnostic medical devices and quasi-drugs in South Korea and internationally. It also develops Rivoceranib, a small-molecule tyrosine kinase inhibitor for the treatment of various cancers, including gastric cancer, colon cancer, hepatocellular carcinoma, non-small cell lung cancer, breast cancer, mesothelioma, renal cell carcinoma, and neuroendocrine tumors; and Pyrotinib, an anticancer drug that inhibits the proliferation, division, and survival of cancer cells. In addition, the co... [Read more]

Sector Utilities
Founded 1998
Employees 145
Stock Exchange KOSDAQ
Ticker Symbol 067630
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.